Scientists in Barcelona have identified a potential new treatment for metabolic liver conditions by repurposing pemafibrate and telmisartan. Preclinical studies showed this drug combination effectively reduced liver fat and improved cholesterol and blood pressure in animal models. This approach could offer a faster, safer, and more accessible solution for MASLD, pending human trials.